Auris Medical Holding AG, of Zug, Switzerland, said it has transfered its listing of common shares to the Nasdaq Capital Market from the Nasdaq Global Market. The company's shares will continue to trade uninterrupted under the symbol EARS. In addition, Nasdaq granted the company an additional 180-day grace period to regain compliance with Nasdaq's minimum bid price requirement. Read More

Ritter Pharmaceuticals Inc., of Los Angeles, filed for an offering of approximately 1.82 million class A units consisting of one common share and one warrant to purchase one common share. Warrants may be exercised once issued and expire five years from the issue date. Read More

Eli Lilly and Co.'s abemaciclib won FDA approval Thursday, making it the third CDK 4/6 inhibitor indicated for treating adults with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy. Read More

Researchers at National Taiwan University (NTU) in Taipei have developed a new stem cell-based treatment modality, which may prevent damage to the growth phase of hair follicles due to cancer therapies. The findings may lead to the first effective treatment for preventing hair loss in cancer patients. Read More

LONDON – Europe's drug discovery supremo, Evotec AG has nailed its colors to the AI mast, making a €15 million (US$17.6 million) investment in artificial intelligence specialist Exscientia Ltd. Read More

BOSTON – How to get around venture capital (VC) firms when raising money in a company's early days yielded a lively panel discussion among alternative funders who explored various routes. Read More

History did not repeat itself for cannabinoid developer Zynerba Pharmaceuticals Inc. A month after shares (NASDAQ:ZYNE) of the Devon, Pa.-based company lost more than half their value following a primary endpoint miss in the phase II study of lead candidate cannabidiol (CBD) gel ZYN-002, which failed to reduce focal seizures in adults with epilepsy, Zynerba rebounded in a big way with top-line findings from the open-label exploratory phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) trial evaluating the same agent in pediatric and adolescent patients with fragile X syndrome (FXS). Read More

PTC Therapeutics Inc.'s bid to convince members of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee that it should recommend approval of the Duchenne muscular dystrophy (DMD) drug Translarna (ataluren) failed on Thursday, with 10 out of 11 members agreeing that, although it's possible the drug may be effective, the data are inconclusive and more work needs to be done. Read More

DUBLIN – Three firms made a late addition to the harvest this year. Deciphera Pharmaceuticals Inc, Nightstar Therapeutics plc and Nucana plc priced IPOs late Thursday, raising $302.5 million in aggregate and taking the total raised from IPOs in the third quarter to $965 million. Read More

CBT Pharmaceuticals Inc., of Pleasanton, Calif., said the first subject was dosed in a phase I study testing CBT-101, a specific oral inhibitor of the c-Met kinase. Following identification of a dose for CBT-101, the 68-patient trial is planned to expand into tumor-specific cohorts. Read More